OTCMLNDZF
Market cap8mUSD
Jan 02, Last price
0.10USD
Name
Salona Global Medical Device Corp
Chart & Performance
Profile
Salona Global Medical Device Corporation, through its subsidiaries, engages in the production and sale of medical devices and products in the United States. The company's medical devices are used for pain management, cold and hot therapy, transcutaneous electronic nerve and neuromuscular electrical stimulation, pulsed electromagnetic field technology, and ultrasound therapy. It also offers wearable technology and products that are used to enhance physical stability. The company was formerly known as Brattle Street Investment Corp. and changed its name to Salona Global Medical Device Corporation in December 2020. Salona Global Medical Device Corporation was incorporated in 2013 and is headquartered in Del Mar, California.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2022‑02 | 2021‑02 | 2020‑02 | 2019‑02 | 2018‑02 | 2017‑02 | 2016‑02 | 2015‑02 | |
Income | ||||||||||
Revenues | 62,627 242.00% | 39,605 -118,158.78% | 18,312 -54,686.90% | |||||||
Cost of revenue | 64,250 | 18,078 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (1,623) | 39,605 | 234 | |||||||
NOPBT Margin | 100.00% | 1.28% | ||||||||
Operating Taxes | 57 | 3,761 | (102) | |||||||
Tax Rate | 9.50% | |||||||||
NOPAT | (1,680) | 35,844 | 335 | |||||||
Net income | (15,603) 256.88% | (19,076) 615.14% | (4,372) 63.90% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 4,262 | |||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 18,007 | 5,917 | ||||||||
Long-term debt | 14,593 | 575 | 8,796 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 34,772 | |||||||||
Net debt | 31,681 | (1,354) | 6,656 | |||||||
Cash flow | ||||||||||
Cash from operating activities | (919) | (993) | (3,704) | |||||||
CAPEX | (203) | (767) | (55) | |||||||
Cash from investing activities | (1,519) | (6,717) | (4,618) | |||||||
Cash from financing activities | 825 | 466 | 3,935 | |||||||
FCF | (9,860) | 24,663 | (5,067) | |||||||
Balance | ||||||||||
Cash | 919 | 1,928 | 8,057 | |||||||
Long term investments | ||||||||||
Excess cash | 7,141 | |||||||||
Stockholders' equity | (9,142) | 7,259 | 6,168 | |||||||
Invested Capital | 37,836 | 52,050 | 17,518 | |||||||
ROIC | 128.76% | 3.17% | ||||||||
ROCE | 76.09% | 0.92% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 73,472 | 54,841 | 43,627 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 862 | 41,775 | 1,076 | |||||||
EV/EBITDA | ||||||||||
Interest | 2,640 | 388 | ||||||||
Interest/NOPBT | 165.97% |